Tweet
Bayer AG (OTCMKTS:BAYRY) â€“ Equities research analysts at Jefferies Financial Group increased their FY2019 earnings per share estimates for shares of Bayer in a report released on Wednesday, August 15th. Jefferies Financial Group analyst I. Hilliker now anticipates that the company will earn $2.29 per share for the year, up from their prior estimate of $2.24. Jefferies Financial Group has a "Hold" rating on the stock. Get Bayer alerts:
A number of other brokerages have also weighed in on BAYRY. ValuEngine lowered Bayer from a "sell" rating to a "strong sell" rating in a research report on Tuesday, August 7th. Zacks Investment Research upgraded Bayer from a "sell" rating to a "hold" rating in a research report on Wednesday, May 2nd. JPMorgan Chase & Co. reiterated a "buy" rating on shares of Bayer in a research report on Monday. Finally, DZ Bank reiterated a "buy" rating on shares of Bayer in a research report on Thursday, May 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company's stock. The stock presently has a consensus rating of "Hold" and an average price target of $36.00. Shares of BAYRY stock opened at $21.86 on Thursday. The firm has a market cap of $87.95 billion, a P/E ratio of 11.51, a PEG ratio of 2.02 and a beta of 1.15. Bayer has a twelve month low of $23.58 and a twelve month high of $35.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.04 and a current ratio of 2.53.
About Bayer
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents